Behavioral Core

项目摘要-行为核心 身体和/或精神创伤是目前疼痛和阿片类药物流行的症结所在。复杂的神经 与疼痛和阿片类药物滥用有关的回路挑战了我们对潜在病理和 潜在的治疗方法。疼痛患者的认知和决策能力肯定会受损。然而， 用于治疗慢性疼痛患者的阿片类化合物本身也与认知有关 减损。尽管阿片使用障碍(OUD)被认为是一种认知障碍，但复合体 在OUD认知模型中驱动这一行为的神经化学信号仍不清楚。我们提出了一个 行为核心将核心3中的神经分析测量与经过基因编辑的动物进行协同 这一联盟将为阿片类药物奖赏和成瘾的机制提供新的有意义的见解 同时验证新的分子靶点和潜伏在OUD下的神经通路。 行为核心将利用DSM-V对阿片类药物使用障碍(OUD)的定义(即，十大 行为范围从个人间和个人内部的功能障碍到导致的身体和心理困难 来自阿片类药物摄入量增加的0-10评分系统)，并将这些应用于动物行为测试，以创建 临床前成瘾研究的类似评分系统，用于可靠的临床翻译应用。这些 行为将与核心-2和核心-3协调执行，以提供最适合 用生物信息学和机器学习策略进行分析。此外，新的分子靶点、治疗方法 将对神经网络进行研究，以确定新的干预措施在多大程度上显著减少了 符合NIH/NIDA的任务。行为核心提供了以下预先建立的分析： SA1-建立成瘾状态的临床前模型，代表ODS的DSM-V标准。 SA2-建立临床前认知模型，用于评估阿片类药物暴露的后果。 SA3-将OUD行为评估与动态神经化学收集相结合。 阿片类药物流行造成的死亡人数不断上升，需要采取更好的干预措施 治疗OUD并更好地了解阿片类药物使用和成瘾的神经回路。要解决这个问题 问题是，我们的研究使用了基于人类OUD患者标准的临床前动物模型。在美国的研究 行为核心专门针对成瘾状态下潜在的认知功能障碍的回路 糟糕的决策、吸毒、维持和复发。我们建议的实验实现了多个 技术方法，将允许理解调节成瘾者认知方面的电路 州政府。从岩心产生的数据最终将导致假设驱动的NIH/NIDA研究提案， 经同行审查的出版物、国家和国际情况介绍和电子数据库系统 科学界将加快发现治疗OUD的有效方法。

Project Summary - Behavioral Core Physical and/or emotional trauma are at the crux of the ongoing pain and opioid epidemics. The complex neural circuitry implicated in pain and opioid misuse challenges our understanding of the underlying pathologies and potential treatments. Cognition and decision-making are certainly impaired in patients with pain. However, the opioids compounds used to treat patients with chronic pain, are themselves also associated with cognitive impairment. Despite the recognition of opioid use disorder (OUD) as a cognitive disorder, the complex neurochemical signaling driving this behavior in cognitive models of OUD remains unclear. We propose a Behavioral Core to synergize the neuro-analytical measurements in Core 3 with the genetically-edited animals in Core 2. This alliance will provide new meaningful insights into the mechanisms of opioid reward and addiction and simultaneously verify new molecular targets and neural pathways underlying OUDs. The Behavioral Core will utilize the DSM-V definition of opioid used disorder (OUD) (i.e., ten major behaviors ranging from inter- and intrapersonal dysfunction to physical and psychological difficulties resulting from increased intake of opioids on a 0-10 scoring system) and apply these to animal behavioral tests to create a similar scoring system for preclinical addiction studies for reliable clinical translational application. These behaviors will be performed in coordination with Cores-2 and Core-3, to provide large data sets optimal for an OUD analysis with bioinformatic and machine learning strategies. In addition, novel molecular targets, therapies and neural networks will be studied to determine to what extent new interventions significantly reduce OUD, in line with the NIH/NIDA mission. The Behavioral Core offer the following pre-established assays: SA1- Establish preclinical models of addictive states that are representative of DSM-V criteria for OUDs. SA2- Establish preclinical models of cognition for evaluation of consequences of opioid exposure. SA3- Integrate OUD behavioral assessment with dynamic neurochemical collection. The escalating number of fatalities from the opioid epidemic necessitates both better interventions to treat OUD and a better understanding of the neural circuits underlying opioid use and addiction. To address this problem, our studies use preclinical animal models based on criteria from human OUD patients. Studies in the Behavioral Core specifically target the circuitry underlying cognitive dysfunction in addictive states that promote poor decision making, drug taking, maintenance and relapse. Our proposed experiments implement multiple technical approaches that will allow for understanding of circuits mediating cognitive aspects of the addictive state. The data generated from the Cores will ultimately lead to hypothesis driven NIH/NIDA research proposals, peer-reviewed publications, national and international presentations and an electronic database system for the scientific community that will speed the discovery of effective therapies for OUD.